Asieris Pharmaceuticals, a global pharma company, announced on Tuesday that it has dosed its first patient in Europe in its multinational, multicentre, Phase III clinical trial (APRICITY) of its photodynamic drug-device combination product APL-1702, Cevira.
The product has been developed as a novel non-surgical treatment of cervical high-grade squamous intraepithelial lesions (HSIL), a pre-cancerous condition caused by a persistent HPV infection.
The study is a multinational, multicentre, randomised, double blind, prospective, placebo-controlled phase III clinical trial to assess the efficacy and safety of APL-1702, Cevira in HSIL. It is an integrated combination of drug and device. Presently, the trial is open for recruitment.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients